

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Oxytetracycline / Diclofenac Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Veterinary product

Recommended restrictions on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Drynam Road
K67 P263 Dublin, Ireland

Telephone : +1-908-740-4000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2	H319: Causes serious eye irritation.
Skin sensitisation, Category 1	H317: May cause an allergic skin reaction.
Reproductive toxicity, Category 1A	H360FD: May damage fertility. May damage the unborn child.
Short-term (acute) aquatic hazard, Category 1	H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1	H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)


SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Hazard pictograms : 

Signal word : Danger

Hazard statements :
H317 May cause an allergic skin reaction.
H319 Causes serious eye irritation.
H360FD May damage fertility. May damage the unborn child.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.
P391 Collect spillage.

Hazardous components which must be listed on the label:

oxytetracycline
Benzyl alcohol

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No.	Classification	Concentration (% w/w)
---------------	--------------------------------	----------------	--------------------------

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version 5.2 Revision Date: 19.05.2025 SDS Number: 1313895-00023 Date of last issue: 14.04.2025
Date of first issue: 20.02.2017

	Registration number		
2-Pyrrolidone	616-45-5 210-483-1	Eye Irrit. 2; H319 Repr. 1B; H360FD specific concentration limit Repr. 1B; H360FD > 3 %	>= 30 - < 50
oxytetracycline	79-57-2 201-212-8	Skin Sens. 1A; H317 Repr. 1A; H360D Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10 M-Factor (Chronic aquatic toxicity): 10	>= 20 - < 25
Benzyl alcohol	100-51-6 202-859-9 603-057-00-5	Acute Tox. 4; H302 Eye Irrit. 2; H319 Skin Sens. 1B; H317 Acute toxicity esti- mate Acute oral toxicity: 1,200 mg/kg	>= 1 - < 10
Sodium [2-[(2,6-dichloro-phenyl)amino]phenyl]acetate	15307-79-6 239-346-4	Acute Tox. 3; H301 Skin Irrit. 2; H315 Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 1; H372 (Gastrointestinal tract, Blood, lymphat- ic system, Liver, Prostate) Aquatic Chronic 2; H411	>= 0.25 - < 1
Sodium hydroxymethanesulphinate	149-44-0 205-739-4	Muta. 2; H341 Repr. 2; H361d EUH032	>= 0.1 - < 1

For explanation of abbreviations see section 16.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

SECTION 4: First aid measures

4.1 Description of first aid measures

- | | | |
|----------------------------|---|---|
| General advice | : | In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : | If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : | In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : | In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention. |
| If swallowed | : | If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |

4.2 Most important symptoms and effects, both acute and delayed

- | | | |
|-------|---|--|
| Risks | : | May cause an allergic skin reaction.
Causes serious eye irritation.
May damage fertility. May damage the unborn child. |
|-------|---|--|

4.3 Indication of any immediate medical attention and special treatment needed

- | | | |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|

SECTION 5: Firefighting measures

5.1 Extinguishing media

- | | | |
|------------------------------|---|--|
| Suitable extinguishing media | : | Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
|------------------------------|---|--|

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- | | | |
|-------------------------|---|--|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing.
Avoid breathing mist or vapours.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

7.2 Conditions for safe storage, including any incompatibilities

- | | | |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations. |
| Advice on common storage | : | Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases |

7.3 Specific end use(s)

- | | | |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version 5.2 Revision Date: 19.05.2025 SDS Number: 1313895-00023 Date of last issue: 14.04.2025
Date of first issue: 20.02.2017

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
oxytetracycline	79-57-2	TWA	500 µg/m ³ (OEB 2)	Internal
Further information: DSEN				
		Wipe limit	100 µg/100 cm ²	Internal
Magnesium oxide	1309-48-4	OELV - 8 hrs (TWA) (Fumes)	5 mg/m ³	IE OEL
		OELV - 8 hrs (TWA) (Respirable dust)	4 mg/m ³	IE OEL
		OELV - 8 hrs (TWA) (inhalable dust)	10 mg/m ³	IE OEL
		OELV - 15 min (STEL) (Fumes)	10 mg/m ³	IE OEL
Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate	15307-79-6	TWA	60 µg/m ³ (OEB 3)	Internal
Further information: Skin				
		Wipe limit	6000 µg/100cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
2-Pyrrolidone	Workers	Inhalation	Long-term systemic effects	57.8 mg/m ³
	Workers	Skin contact	Long-term systemic effects	10 mg/kg bw/day
	Workers	Skin contact	Acute systemic effects	277 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	17.1 mg/m ³
	Consumers	Skin contact	Long-term systemic effects	6 mg/kg bw/day
	Consumers	Skin contact	Acute systemic effects	167 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	5.2 mg/kg bw/day
	Consumers	Ingestion	Acute systemic effects	33.3 mg/kg bw/day
Benzyl alcohol	Workers	Inhalation	Long-term systemic effects	22 mg/m ³

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version 5.2 Revision Date: 19.05.2025 SDS Number: 1313895-00023 Date of last issue: 14.04.2025
Date of first issue: 20.02.2017

	Workers	Inhalation	Acute systemic ef- fects	110 mg/m3
	Workers	Skin contact	Long-term systemic effects	8 mg/kg bw/day
	Workers	Skin contact	Acute systemic ef- fects	40 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	5.4 mg/m3
	Consumers	Inhalation	Acute systemic ef- fects	27 mg/m3
	Consumers	Skin contact	Long-term systemic effects	4 mg/kg bw/day
	Consumers	Skin contact	Acute systemic ef- fects	20 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	4 mg/kg bw/day
	Consumers	Ingestion	Acute systemic ef- fects	20 mg/kg bw/day
Sodium hy- droxymethanesulphi- nate	Workers	Inhalation	Long-term systemic effects	21 mg/m3
	Workers	Inhalation	Acute systemic ef- fects	140 mg/m3
	Workers	Skin contact	Long-term systemic effects	6 mg/kg bw/day
	Workers	Skin contact	Acute systemic ef- fects	40 mg/kg bw/day
	Workers	Skin contact	Acute local effects	0.225 mg/cm2

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
oxytetracycline	Fresh water	0.0003 mg/l
	Marine water	0.0003 mg/l
2-Pyrrolidone	Fresh water	0.5 mg/l
	Freshwater - intermittent	0.5 mg/l
	Marine water	0.05 mg/l
	Sewage treatment plant	10 mg/l
	Fresh water sediment	0.4205 mg/kg dry weight (d.w.)
	Soil	0.0612 mg/kg dry weight (d.w.)
Benzyl alcohol	Fresh water	1 mg/l
	Marine water	0.1 mg/l
	Intermittent use/release	2.3 mg/l
	Sewage treatment plant	39 mg/l
	Fresh water sediment	5.27 mg/kg
	Marine sediment	0.527 mg/kg
Sodium hydroxymethanesulphi- nate	Soil	0.456 mg/kg
	Fresh water	0.056 mg/l
	Marine water	0.006 mg/l

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

	Freshwater - intermittent	0.056 mg/l
	Sewage treatment plant	1 mg/l
	Fresh water sediment	0.046 mg/kg dry weight (d.w.)
	Marine sediment	0.005 mg/kg dry weight (d.w.)
	Soil	0.011 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection
Material : Chemical-resistant gloves

Remarks : Consider double gloving.
Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Filter should conform to I.S. EN 14387
Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : liquid

Colour : light brown

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
pH	:	8.3 - 9.0 (as aqueous solution)
Viscosity		
Viscosity, kinematic	:	47.62 mm ² /s
Solubility(ies)		
Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	No data available
Vapour pressure	:	No data available
Relative density	:	No data available
Density	:	1.05 - 1.18 g/cm ³
Relative vapour density	:	No data available
Particle characteristics		
Particle size	:	Not applicable

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

9.2 Other information

Explosives	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Evaporation rate	:	No data available
Molecular weight	:	No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

2-Pyrrolidone:

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 401
Assessment: The substance or mixture has no acute oral toxicity

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

oxytetracycline:

Acute oral toxicity : LD50 (Rat): 4,800 mg/kg

LD50 (Mouse): 2,240 mg/kg
Remarks: Evidence of phototoxicity was observed

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): 4,840 mg/kg
Application Route: Intramuscular

LD50 (Mouse): 3,500 mg/kg
Application Route: Subcutaneous

Benzyl alcohol:

Acute oral toxicity : LD50 (Rat): 1,200 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.4 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Assessment: The substance or mixture has no acute inhalation toxicity

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Acute oral toxicity : LD50 (Rat): 55 - 240 mg/kg

LD50 (Mouse): 170 - 389 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 97 - 161 mg/kg
Application Route: Intravenous

LD50 (Mouse): 92 - 147 mg/kg
Application Route: Intravenous

Sodium hydroxymethanesulphonate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral toxicity

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

2-Pyrrolidone:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

oxytetracycline:

Remarks : No data available

Benzyl alcohol:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Result : irritating

Sodium hydroxymethanesulphinate:

Species : Rat
Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

2-Pyrrolidone:

Species : Rabbit
Result : Irritation to eyes, reversing within 7 days

oxytetracycline:

Remarks : No data available

Benzyl alcohol:

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Species	:	Rabbit
Method	:	OECD Test Guideline 405
Result	:	Irritation to eyes, reversing within 21 days

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Result	:	Mild eye irritation
--------	---	---------------------

Sodium hydroxymethanesulphinate:

Species	:	Rabbit
Method	:	OECD Test Guideline 405
Result	:	No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Components:

2-Pyrrolidone:

Test Type	:	Local lymph node assay (LLNA)
Exposure routes	:	Skin contact
Species	:	Mouse
Method	:	OECD Test Guideline 429
Result	:	negative
Remarks	:	Based on data from similar materials

oxytetracycline:

Test Type	:	Human repeat insult patch test (HRIPT)
Result	:	Sensitiser

Benzyl alcohol:

Test Type	:	Human repeat insult patch test (HRIPT)
Exposure routes	:	Skin contact
Species	:	Humans
Result	:	positive

Assessment	:	Probability or evidence of low to moderate skin sensitisation rate in humans
------------	---	--

Sodium hydroxymethanesulphinate:

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

2-Pyrrolidone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo
cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Method: OECD Test Guideline 474
Result: negative

oxytetracycline:

Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)
Result: negative

Test Type: Mouse Lymphoma
Metabolic activation: Metabolic activation
Result: positive

Test Type: sister chromatid exchange assay
Test system: Chinese hamster ovary cells
Result: equivocal

Test Type: Chromosomal aberration
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: equivocal

Test Type: in vivo assay
Species: Mouse
Application Route: Intraperitoneal injection

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Benzyl alcohol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration
Species: CHO
Result: negative

Sodium hydroxymethanesulphinate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Method: OECD Test Guideline 474
Result: positive

Germ cell mutagenicity- Assessment : Positive result(s) from in vivo mammalian somatic cell mutagenicity tests.

Carcinogenicity

Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Components:

2-Pyrrolidone:

Species	:	Mouse
Application Route	:	Ingestion
Exposure time	:	18 month(s)
Result	:	negative
Remarks	:	Based on data from similar materials

oxytetracycline:

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	104 weeks
Result	:	negative

Species	:	Rat
Application Route	:	Oral
Exposure time	:	103 weeks
Result	:	equivocal
Target Organs	:	Adrenal gland, Pituitary gland
Remarks	:	The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment	:	Weight of evidence does not support classification as a carcinogen
------------------------------	---	--

Benzyl alcohol:

Species	:	Mouse
Application Route	:	Ingestion
Exposure time	:	103 weeks
Method	:	OECD Test Guideline 451
Result	:	negative

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
Result	:	negative

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	2 Years
Result	:	negative

Reproductive toxicity

May damage fertility. May damage the unborn child.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Components:

2-Pyrrolidone:

- Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: positive
Remarks: Based on data from similar materials
- Effects on foetal develop-
ment : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: positive
- Reproductive toxicity - As-
sessment : Clear evidence of adverse effects on sexual function and fertil-
ity, based on animal experiments., Clear evidence of adverse
effects on development, based on animal experiments.

oxytetracycline:

- Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 18 mg/kg body weight
Result: No effects on fertility, No effect on reproduction capac-
ity, No significant adverse effects were reported
- Effects on foetal develop-
ment : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: LOAEL: 48 mg/kg body weight
Result: Postimplantation loss., Skeletal malformations
- Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
General Toxicity Maternal: LOAEL: 1,200 mg/kg body weight
Embryo-foetal toxicity: NOAEL: 1,500 mg/kg body weight
Result: No teratogenic effects
Remarks: Maternal toxicity observed.
- Test Type: Embryo-foetal development
Species: Mouse
Application Route: Oral
General Toxicity Maternal: LOAEL: 1,325 mg/kg body weight
Embryo-foetal toxicity: NOAEL: 2,100 mg/kg body weight
Result: No teratogenic effects
Remarks: Maternal toxicity observed.
- Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Intramuscular

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Embryo-foetal toxicity: LOAEL: 41.5 mg/kg body weight
Result: Postimplantation loss., No foetal abnormalities

Test Type: Embryo-foetal development
Species: Dog
Application Route: Intramuscular
Embryo-foetal toxicity: LOAEL: 20.75 mg/kg body weight
Result: Skeletal and visceral variations, Postimplantation loss.

Reproductive toxicity - Assessment : Positive evidence of adverse effects on development from human epidemiological studies.

Benzyl alcohol:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Mouse
Application Route: Ingestion
Result: negative

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Effects on fertility : Test Type: Fertility
Species: Rat, male and female
Application Route: Oral
Fertility: NOAEL: 4 mg/kg body weight
Result: No effects on fertility

Effects on foetal development : Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 1 mg/kg body weight
Result: Embryo-foetal toxicity, No teratogenic effects

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 5 mg/kg body weight
Result: Embryo-foetal toxicity, No teratogenic effects

Reproductive toxicity - Assessment : Suspected of damaging the unborn child.

Sodium hydroxymethanesulphinate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative

Effects on foetal develop-
ment : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive

Reproductive toxicity - As-
sessment : Some evidence of adverse effects on development, based on
animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Target Organs : Gastrointestinal tract, Blood, lymphatic system, Liver, Prostate
Assessment : Causes damage to organs through prolonged or repeated
exposure.

Repeated dose toxicity

Components:

2-Pyrrolidone:

Species : Rat
NOAEL : 207 mg/kg
Application Route : Ingestion
Exposure time : 3 Months
Method : OECD Test Guideline 408

oxytetracycline:

Species : Rat
LOAEL : 198 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Bone
Remarks : No significant adverse effects were reported

Species : Mouse
LOAEL : 7,990 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Bone
Remarks : No significant adverse effects were reported

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Species	: Dog
NOAEL	: 125 mg/kg
LOAEL	: 250 mg/kg
Application Route	: Oral
Exposure time	: 12 Months
Target Organs	: Testis
Remarks	: Significant toxicity observed in testing

Species	: Rat
NOAEL	: 40 mg/kg
LOAEL	: 100 mg/kg
Application Route	: Intraperitoneal
Exposure time	: 14 Days
Target Organs	: Kidney

Benzyl alcohol:

Species	: Rat
NOAEL	: 1.072 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 28 Days
Method	: OECD Test Guideline 412

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Species	: Rat
LOAEL	: 0.25 mg/kg
Application Route	: Oral
Exposure time	: 98 w
Target Organs	: Gastrointestinal tract, Blood, lymphatic system, Liver, Prostate

Species	: Dog
LOAEL	: 1 mg/kg
Application Route	: Oral
Exposure time	: 12 w
Target Organs	: Blood

Species	: Baboon
NOAEL	: 0.5 mg/kg
LOAEL	: 5 mg/kg
Application Route	: Oral
Exposure time	: 52 w
Target Organs	: Gastrointestinal tract, Blood
Symptoms	: constipation, Diarrhoea

Sodium hydroxymethanesulphinate:

Species	: Rat
NOAEL	: 600 mg/kg
Application Route	: Ingestion
Exposure time	: 13 Weeks

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Method : OECD Test Guideline 408

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Not classified based on available information.

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

oxytetracycline:

Ingestion : Symptoms: Gastrointestinal disturbance, tooth discoloration
Remarks: May cause birth defects.

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Ingestion : Symptoms: Abdominal pain, Diarrhoea, constipation, heart-burn, Ulceration, Dizziness, Headache, Breathing difficulties, Rash

SECTION 12: Ecological information

12.1 Toxicity

Components:

2-Pyrrolidone:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 4,600 - 10,000 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 500 mg/l
aquatic invertebrates Exposure time: 48 h

Toxicity to algae/aquatic : ErC50 (Desmodesmus subspicatus (green algae)): > 500 mg/l
plants Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 22.2 mg/l
Exposure time: 72 h

Toxicity to microorganisms : EC50 : > 1,000 mg/l

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Exposure time: 30 min
Method: OECD Test Guideline 209

oxytetracycline:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 110 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 621 mg/l
aquatic invertebrates Exposure time: 48 h
Method: OECD Test Guideline 202

EC50 (Moina macrocopa (Water flea)): 126.7 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic : EC50 (Anabaena): 0.032 mg/l
plants Exposure time: 72 h

NOEC (Anabaena): 0.0031 mg/l
Exposure time: 72 h

M-Factor (Acute aquatic tox- : 10
icity)

Toxicity to microorganisms : EC50 (activated sludge): 17.9 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC (activated sludge): 0.2 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

M-Factor (Chronic aquatic : 10
toxicity)

Benzyl alcohol:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 460 mg/l
Exposure time: 96 h

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 230 mg/l
aquatic invertebrates Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic : EC50 (Pseudokirchneriella subcapitata (green algae)): 770
plants mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

NOEC (Pseudokirchneriella subcapitata (green algae)): 310 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 51 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 166.6 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 80.1 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 71.9 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 49.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC: 0.32 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 10 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

Sodium hydroxymethanesulphonate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 10,000 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): 370 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

NOEC (Desmodesmus subspicatus (green algae)): 10 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : NOEC : 10 mg/l
Exposure time: 4 h

Toxicity to fish (Chronic tox- : NOEC: 13.5 mg/l
icity) Exposure time: 35 d
Species: Danio rerio (zebra fish)
Method: OECD Test Guideline 210

Toxicity to daphnia and other : EC10: 8 mg/l
aquatic invertebrates (Chron- Exposure time: 21 d
ic toxicity) Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

12.2 Persistence and degradability

Components:

2-Pyrrolidone:

Biodegradability : Result: Readily biodegradable.
Remarks: Based on data from similar materials

Benzyl alcohol:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 92 - 96 %
Exposure time: 14 d

Sodium hydroxymethanesulphinate:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 77 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

12.3 Bioaccumulative potential

Components:

2-Pyrrolidone:

Partition coefficient: n- : log Pow: -0.71
octanol/water Method: OECD Test Guideline 107

Benzyl alcohol:

Partition coefficient: n- : log Pow: 1.05
octanol/water

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Partition coefficient: n-
octanol/water : log Pow: 4.51

Sodium hydroxymethanesulphinate:

Partition coefficient: n-
octanol/water : log Pow: < 0.3

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : UN 3082

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

ADR : UN 3082

RID : UN 3082

IMDG : UN 3082

IATA : UN 3082

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
N.O.S.
(Oxytetracycline)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
N.O.S.
(Oxytetracycline)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
N.O.S.
(Oxytetracycline)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
N.O.S.
(Oxytetracycline)

IATA : Environmentally hazardous substance, liquid, n.o.s.
(Oxytetracycline)

14.3 Transport hazard class(es)

	Class	Subsidiary risks
ADN	: 9	
ADR	: 9	
RID	: 9	
IMDG	: 9	
IATA	: 9	

14.4 Packing group

ADN
Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

ADR
Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

RID

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passenger aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:
Number on list 3

Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable

Regulation (EU) No 2024/590 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

E1	ENVIRONMENTAL HAZARDS	Quantity 1 100 t	Quantity 2 200 t
----	--------------------------	---------------------	---------------------

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H301	: Toxic if swallowed.
H302	: Harmful if swallowed.
H315	: Causes skin irritation.
H317	: May cause an allergic skin reaction.
H319	: Causes serious eye irritation.
H341	: Suspected of causing genetic defects.
H360D	: May damage the unborn child.
H360FD	: May damage fertility. May damage the unborn child.
H361d	: Suspected of damaging the unborn child.
H372	: Causes damage to organs through prolonged or repeated exposure.
H400	: Very toxic to aquatic life.
H410	: Very toxic to aquatic life with long lasting effects.
H411	: Toxic to aquatic life with long lasting effects.
EUH032	: Contact with acids liberates very toxic gas.

Full text of other abbreviations

Acute Tox.	: Acute toxicity
Aquatic Acute	: Short-term (acute) aquatic hazard
Aquatic Chronic	: Long-term (chronic) aquatic hazard
Eye Irrit.	: Eye irritation
Muta.	: Germ cell mutagenicity
Repr.	: Reproductive toxicity
Skin Irrit.	: Skin irritation
Skin Sens.	: Skin sensitisation
STOT RE	: Specific target organ toxicity - repeated exposure
IE OEL	: Ireland. List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2
IE OEL / OELV - 8 hrs (TWA)	: Occupational exposure limit value (8-hour reference period)
IE OEL / OELV - 15 min (STEL)	: Occupational exposure limit value (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regula-

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

tion (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Eye Irrit. 2	H319
Skin Sens. 1	H317
Repr. 1A	H360FD
Aquatic Acute 1	H400
Aquatic Chronic 1	H410

Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Liquid Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
5.2	19.05.2025	1313895-00023	Date of first issue: 20.02.2017

IE / EN